Evidence profile
TB-500
TB-500 study rows link each listed finding to its source, model or population, and endpoint.
Cited headline finding
The full-length thymosin beta-4 study reported endothelial migration and angiogenesis findings; the study does not establish those findings for the TB-500 fragment. ↗
Human umbilical-vein endothelial cells and migration assaysMalinda, Goldstein & Kleinman, FASEB Journal 1997In vitro
Mechanism scope
How cited research characterizes TB-500
The cited study characterizes full-length thymosin beta-4, rather than the TB-500 fragment, in endothelial migration and angiogenesis assays.
Sources: Malinda, Goldstein & Kleinman, FASEB Journal 1997 ↗
Open question
What the cited TB-500 sources do not resolve
The cited full-length thymosin beta-4 study does not answer whether TB-500 produces the same findings.
Sources: Malinda, Goldstein & Kleinman, FASEB Journal 1997 ↗
| Finding | Year | n | Model or population | Endpoint | Source | Evidence tier |
|---|---|---|---|---|---|---|
| The full-length thymosin beta-4 study reported endothelial migration and angiogenesis findings; the study does not establish those findings for the TB-500 fragment. | 1997 | Not stated | Human umbilical-vein endothelial cells and migration assays | Endothelial migration and angiogenesis | Malinda, Goldstein & Kleinman, FASEB Journal 1997 ↗ | In vitro |
Regulatory status
TB-500 appears in Health Canada's peptide-drug advisory. ↗
Related source
Source notes
Reviewer: Ember Peptides source-verification editorial review · Review date: 2026-09-13